Transcatheter aortic valve implantation (TAVI) is an established therapeutic option for high-risk patients with a tricuspid aortic valve, but patients with a bicuspid aortic valve (BAV) are contraindicated. In this Perspectives article, Zhao and colleagues summarize the available evidence for the use of TAVI in patients with a BAV and propose that this procedure might be appropriate in high-risk or inoperable individuals, but that more evidence is required before indications for TAVI can be extended to other patients with a BAV.
- Zhen-Gang Zhao
- Hasan Jilaihawi
- Mao Chen
